Exubera And Vivitrol FDA Approvals Drive Renewed Interest And Investment In Drug Delivery Technologies

Main Category: Immune System / Vaccines
Also Included In: Pharma Industry / Biotech Industry
Article Date: 05 Aug 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

Recent approvals of new products employing drug delivery technologies have served to provide an important catalyst for ongoing development of systems in development as well as renewed funding of early stage and clinical activities, reports Mark Alexay of Strategic Research Institute. Many late-stage clinical development products for delivery via through needlefree, microneedle, injectable, nasal/pulmonary, transdermal, combination products, reformulated generics, and enhanced solubilization and controlled release, and many other routes are vying for market entry in late 2006 and 2007.

The 11th Annual Drug Delivery Technologies & Deal-Making Summit, a leading industry-focused meeting on the business and new science of the field is slated to take place in New Brunswick, New Jersey from September 25-27. The conference and exposition annually attracts hundreds of executive attendees from around the world. Executive keynote panels to kick off the meeting are scheduled for September 26 and 27. Top level executives will address the following topics:

New Partnerships and Investment in Drug Delivery and Specialty Pharmaceutical Companies

-- Phyllis Gardner, M.D., Associate Professor of Medicine, Stanford University School of Medicine

-- Todd Brady, Principal, Domain Associates

-- Arthur Klausner, Partner, Pappas Ventures

-- Bill Slattery, Partner, Deerfield Management

-- Alex Zisson, Venture Partner, Thomas, McNerney & Partners

Pharma's View on Drug Delivery

-- Ralph Vitaro, Publisher/President, Drug Delivery Technology

-- Mandana Asgharnejad, Ph.D., Director, Scientific Liaison - External Scientific Affairs, Merck & Co., Inc.

-- Frank Grams, Global Head Drug Delivery Partnering, Roche

-- Keith R. Horspool, Ph.D., Assistant Director, Pharmaceutical R & D, Pfizer, Inc.

-- Ian McKenna, Alliance Management for Early-Stage Technologies and Biotechnology, Eli Lilly & Company

-- Matthew D. Roe, Senior Director, Business Development and Licensing, Genzyme Pharmaceuticals

-- Ronald L. Smith, Ph.D., Executive Director, Biopharmaceutics R&D, Bristol-Myers Squibb

Parameters of Performance - Driving Drug Delivery Value and Valuation

-- Josef Bossart, Ph.D., Principal, B4Bio

-- Guy Furness, Managing Director, ONdrugDelivery Ltd

-- Brian S. Gorin, Managing Principal, Analysis Group Inc.

-- Deborah Neveille, Director, Business Analysis, Elan Pharmaceuticals

-- Ken Andrews, Alkermes

-- Franck Ziser, VP New Product and Technology Development, Worldwide Product Planning Group, Cephalon -- Christopher Searcy, PharmD., MBA, Vice President Corporate Development, Nektar Therapeutics Developing Products: How Do Emerging Drug Delivery Companies Support The Cost?

-- John M. Siebert, Chairman and CEO, CyDex, Inc.

-- Todd C. Davis, Partner, Paul Capital Partners

-- Ed Saltzman, President, Defined Health

-- Chris Seiter, Managing Director, Head of Specialty Pharmaceuticals, Bank of America

-- Andrew Forman, Senior Analyst and Managing Director, WR Hambrecht + Co

-- Jack Khattar, President & CEO, Supernus Pharmaceuticals, Inc.

Specialty Pharma Pipeline - Build or Buy?

-- Debra Bingham, Partner, Valeo Partners

-- Mary Furlong, Executive Vice President, Corporate Development, Lupin Ltd

-- Tim Howard, Partner, Stonecroft Capital LLC

-- Ravi Kiron, Ph.D., MBA, Executive Director, New Technology Assessment and Planning, Alza Corporation (a division of Johnson & Johnson)

-- Christine Mayer, Vice President, Business Development, Biovail Pharmaceuticals

Strategic Research Institute
http://www.srinstitute.com

• Additional
• References
• Citations